Cargando…
Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease
SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in ∼80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options are availa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434373/ https://www.ncbi.nlm.nih.gov/pubmed/29893938 http://dx.doi.org/10.1093/rheumatology/key151 |
_version_ | 1783406468739891200 |
---|---|
author | Khanna, Dinesh Tashkin, Donald P Denton, Christopher P Lubell, Martin W Vazquez-Mateo, Cristina Wax, Stephen |
author_facet | Khanna, Dinesh Tashkin, Donald P Denton, Christopher P Lubell, Martin W Vazquez-Mateo, Cristina Wax, Stephen |
author_sort | Khanna, Dinesh |
collection | PubMed |
description | SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in ∼80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options are available. CYC is included in treatment guidelines, but it has limited efficacy and is associated with toxicity. MMF is becoming the most commonly used medication in clinical practice in North America and the UK, but its use is not universal. Newer agents targeting the pathogenic mechanisms underlying SSc-ILD, including fibrotic and inflammatory pathways, lymphocytes, cell–cell and cell–extracellular membrane interactions, hold promise for better treatment outcomes, including improved lung function, patient-related outcomes and quality of life. Here we review ongoing trials of established and novel agents that are currently recruiting patients with SSc-ILD. |
format | Online Article Text |
id | pubmed-6434373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64343732019-04-01 Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease Khanna, Dinesh Tashkin, Donald P Denton, Christopher P Lubell, Martin W Vazquez-Mateo, Cristina Wax, Stephen Rheumatology (Oxford) Reviews SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in ∼80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options are available. CYC is included in treatment guidelines, but it has limited efficacy and is associated with toxicity. MMF is becoming the most commonly used medication in clinical practice in North America and the UK, but its use is not universal. Newer agents targeting the pathogenic mechanisms underlying SSc-ILD, including fibrotic and inflammatory pathways, lymphocytes, cell–cell and cell–extracellular membrane interactions, hold promise for better treatment outcomes, including improved lung function, patient-related outcomes and quality of life. Here we review ongoing trials of established and novel agents that are currently recruiting patients with SSc-ILD. Oxford University Press 2019-04 2018-06-08 /pmc/articles/PMC6434373/ /pubmed/29893938 http://dx.doi.org/10.1093/rheumatology/key151 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Reviews Khanna, Dinesh Tashkin, Donald P Denton, Christopher P Lubell, Martin W Vazquez-Mateo, Cristina Wax, Stephen Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease |
title | Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease |
title_full | Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease |
title_fullStr | Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease |
title_full_unstemmed | Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease |
title_short | Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease |
title_sort | ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434373/ https://www.ncbi.nlm.nih.gov/pubmed/29893938 http://dx.doi.org/10.1093/rheumatology/key151 |
work_keys_str_mv | AT khannadinesh ongoingclinicaltrialsandtreatmentoptionsforpatientswithsystemicsclerosisassociatedinterstitiallungdisease AT tashkindonaldp ongoingclinicaltrialsandtreatmentoptionsforpatientswithsystemicsclerosisassociatedinterstitiallungdisease AT dentonchristopherp ongoingclinicaltrialsandtreatmentoptionsforpatientswithsystemicsclerosisassociatedinterstitiallungdisease AT lubellmartinw ongoingclinicaltrialsandtreatmentoptionsforpatientswithsystemicsclerosisassociatedinterstitiallungdisease AT vazquezmateocristina ongoingclinicaltrialsandtreatmentoptionsforpatientswithsystemicsclerosisassociatedinterstitiallungdisease AT waxstephen ongoingclinicaltrialsandtreatmentoptionsforpatientswithsystemicsclerosisassociatedinterstitiallungdisease |